About usOur ApproachOur PipelinePatientsInvestorsCareers

You are leaving Spyre

If you would like to proceed, click the link to continue.
https://twitter.com/

Go back
Continue
Spyre is not responsible for content on external websites.
Please review their Privacy Policy.

Our Pipeline

Our pipeline of novel antibodies targets validated mechanisms with the potential to treat several immune-mediated conditions
A 3D visualization of the SPY001 and SPY002 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing shade.A 3D visualization of the SPY001 and SPY002 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing shade.
Therapeutic area
Indication
Program
Target
Phase 1
Phase 2
Phase 3
Anticipated Milestones
Therapeutic area

Gastroenterology

Indication:
UC
Program:
SPY120
Target:
a4B7 + TL-1A
Phase 2
Anticipated Milestones:
3Q 2027:
Ph2 POC
Indication:
UC
Program:
SPY130
Target:
a4B7 + IL-23
Phase 2
Anticipated Milestones:
3Q 2027:
Ph2 POC
Indication:
UC
Program:
SPY230
Target:
TL1A + IL-23
Phase 2
Anticipated Milestones:
3Q 2027:
Ph2 POC
Indication:
UC
Program:
SPY001
Target:
a4B7
Phase 2
Anticipated Milestones:
Q3 2027:
Ph2 POC
Indication:
UC
Program:
SPY002
Target:
TL1A
Phase 2
Anticipated Milestones:
3Q 2027:
Ph2 POC
Indication:
UC
Program:
SPY003
Target:
IL-23
Phase 2
Anticipated Milestones:
3Q 2027:
Ph2 POC
Therapeutic area

Dermatology

Indication:
HS
Program:
SPY072
Target:
TL1A
Phase 2
Anticipated Milestones:
2027:
Pivotal trial initiation
Indication:
HS
Program:
SPY772
Target:
TL1A + IL-17A/F
Phase 2
Anticipated Milestones:
Late '27/ Early '28:
Ph2 POC

Our programs

SPY001

SPY001 is a novel, half-life extended monoclonal antibody targeting α4β7 for the potential treatment of IBD

In head-to-head preclinical studies, SPY001 demonstrated similar potency and selectivity as vedolizumab
Interim Phase 1 results demonstrated SPY001 was well tolerated, exhibited a differentiated PK profile supporting potential quarterly or twice annual maintenance dosing, and rapid and sustained target engagement
SPY001 is being evaluated in the Phase 2 SKYLINE trial in UC patients
SPY001 antibody
SPY002

SPY002 is a novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of IBD

In head-to-head preclinical studies, SPY002 exhibited comparable or superior potency to first-generation anti-TL1As
Interim Phase 1 results demonstrated SPY002 was well tolerated, exhibited a differentiated PK profile supporting potential quarterly or twice annual maintenance dosing, and rapid and sustained target engagement
SPY002 is being evaluated in the Phase 2 SKYLINE trial in UC patients
SPY002 antibody
SPY003

SPY003 is a novel, half-life extended monoclonal antibody targeting IL-23 for the potential treatment of IBD

In head-to-head preclinical studies, SPY003 exhibited comparable potency to risankizumab
Interim Phase 1 results demonstrated SPY003 was well tolerated and exhibited a differentiated PK profile supporting potentially quarterly or twice annual maintenance dosing.
SPY003 is being evaluated in the Phase 2 SKYLINE trial in UC patients
SPY003 antibody
SPY120

SPY120 is a combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) for the potential treatment of IBD

In preclinical models of colitis, combined inhibition of α4β7 and TL1A resulted in superior efficacy compared to either monotherapy alone
High-concentration coformulation data support potential for delivery in a single injector with chronic administration on a quarterly or twice annual basis.
SPY120 is being evaluated in the Phase 2 SKYLINE trial in UC patients
SPY120 combination
SPY130

SPY130 is a combination of SPY001 (anti-α4β7) and SPY003 (anti-IL-23) for the potential treatment of IBD

In preclinical models of colitis, combined inhibition of α4β7 and IL-23 resulted in additive efficacy of either monotherapy alone
High-concentration coformulation data support potential for delivery in a single injector with chronic administration on a quarterly or twice annual basis.
SPY130 is being evaluated in the Phase 2 SKYLINE trial in UC patients
SPY130 combination
SPY230

SPY230 is a combination of SPY002 (anti-TL1A) and SPY003 (anti-IL-23) for the potential treatment of IBD

In preclinical models of colitis, combined inhibition of TL1A and IL-23 resulted in additive efficacy of either monotherapy alone
High-concentration coformulation data support potential for delivery in a single injector with chronic administration on a quarterly or twice annual basis.
SPY230 is being evaluated in the Phase 2 SKYLINE trial in UC patients
SPY230 combination
SPY072

SPY072 is a novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment HS

SPY072 is a distinct anti-TL1A molecule from SPY002, which is being studied in IBD. Interim Phase 1 results demonstrated SPY072 was well tolerated, exhibited a differentiated PK profile supporting potential quarterly maintenance dosing, and rapid and sustained target engagement
A pivotal trial of SPY072 in HS patients is planned for 2027
SPY072 antibody
SPY772

SPY772 is a combination of SPY007 (anti-IL-17A/F) and SPY072 (anti-TL1A) for the potential treatment of HS

Pairs two validated mechanisms of action designed to target multiple inflammatory pathways involved in HS
Designed to be coformulated in an autoinjector for infrequent chronic administration
SKYLIGHT trial is evaluating SPY072 as an add-on to IL-17A/F as a surrogate POC for SPY772 in HS patient
SPY772 antibody

Product candidates discussed are investigational and currently being studied in clinical trials. Their safety and efficacy have not been established and they have not been approved for any use by FDA, the European Commission, or any other health authority.